Varicella zoster immune globulin (human) (VARIZIG) in immunocompromised patients: a subgroup analysis for safety and outcomes from a large, expanded-access program

Hayley Gans* and Roy F. Chemaly

Abstract

Background: Immunocompromised children and adults are at increased risk for severe disease and death following varicella zoster virus infection. Varicella zoster immune globulin (human) (VARIZIG) is recommended for post-exposure prophylaxis to prevent or attenuate varicella infection in high-risk individuals.

Methods: An open-label, expanded-access program provided VARIZIG to high-risk individuals exposed to varicella or herpes zoster. Immunocompromised participants were stratified by type of immunocompromising condition (“oncologic immunodeficiency”, “primary immunodeficiency”, “solid organ transplant” [SOT], “hematopoietic cell transplant” [HCT], and “other”). Patient characteristics, type of exposure and varicella outcome, and safety data were assessed.

Results: This analysis included 40 adults (primary [n = 6] or oncologic [n = 10] immunodeficiencies, history of SOT [n = 5] or HCT [n = 6], and other [n = 13]), and 263 children (primary [n = 13] or oncologic [n = 152] immunodeficiencies, history of SOT [n = 36] or HCT [n = 17], and other [n = 45]). Among adults and children, 48% vs 72% were exposed to varicella, 38% vs 16% were exposed to herpes zoster, and 15% vs 12% had an unspecified exposure. Overall incidence of varicella infection in adults after VARIZIG use was 6%; incidence of varicella infection in children after VARIZIG use was 7%. Similar rates were noted in each subgroup. Most cases of varicella were mild, with two children developing > 100 lesions and no cases of varicella-related pneumonia or encephalitis. Varicella-related hospitalizations occurred primarily in children with oncologic immunodeficiencies. One serious adverse event (serum sickness) was considered related to VARIZIG and occurred in a child with oncologic immunodeficiency. There were no varicella- or VARIZIG-related deaths.

Conclusions: These data indicate that VARIZIG may reduce severity of varicella in immunocompromised children and adults.

(Continued on next page)
Background
Immunocompromised children and adults are at increased risk for severe disease following infection with varicella zoster virus (VZV) [1, 2], including an increased risk of visceral dissemination (i.e. varicella-related pneumonia, encephalitis, hepatitis), secondary bacterial infections, and mortality [2–5]. Even in individuals who previously received two doses of varicella vaccine, an important risk factor is waning immunity as a result of immunosuppressive therapy [6].

Advancements in cancer therapy, the availability of new immunosuppressant medications, and increased rates and survival of organ transplant recipients receiving prolonged immune suppression have resulted in an increased number of immunocompromised children and adults [7, 8]. Varicella vaccination is contraindicated in immunocompromised individuals, including those with malignancies and those receiving high-dose systemic immunosuppressive therapy [9]. Passive immunization after exposure with immune globulin specifically targeting VZV has been shown to reduce the severity of varicella infection, and is the generally accepted strategy for prevention in exposed immunocompromised individuals [10–12]. Although there is no official guidance on use of antiviral prophylaxis after varicella exposure, use of antiviral therapy started between 6 and 10 days after exposure and continued for 7 days has been reported to prevent varicella infection after exposure [13].

Varicella zoster immune globulin (human) (VARIZIG, Saol Therapeutics, Roswell, GA, USA) is recommended for post-exposure prophylaxis to prevent or reduce varicella infection in high-risk individuals [9, 12, 14]. VARIZIG is recommended to be administered as soon as possible after varicella or herpes zoster exposure (ideally within 96 h); however, the Centers for Disease Control and Prevention suggests that administration can be as late as 10 days after exposure [12]. An expanded-access program assessed the incidence and severity of varicella infections after post-exposure prophylaxis with VARIZIG in a real-world setting in several high-risk populations, including immunocompromised patients [15]. Although passive immunization is the recommended method for addressing varicella or herpes zoster exposure in immunocompromised individuals, there are limited published data describing varicella incidence and clinical outcomes in patients receiving VARIZIG. As such, we stratified immunocompromised adults and children by type of underlying condition, including primary immunodeficiency, oncology, solid organ transplant (SOT), hematopoietic cell transplant (HCT), and other conditions and analyzed varicella outcome and safety data from the expanded-access program.

Methods
Participants
Physician-identified, high-risk individuals who were exposed to varicella or herpes zoster were eligible for inclusion in the study. High-risk participants included immunocompromised children and adults, among others (e.g. preterm infants, in utero–exposed newborns, pregnant women). A full report of the study has been previously published [15]. This analysis focuses on the immunocompromised participants, providing an in-depth analysis of the subgroups within this heterogeneous population. The protocol did not specify what constituted an exposure to varicella or herpes zoster, and was left to the judgment of the investigator. The timing of administration post-exposure was defined based on information provided to the investigator by the participant or family member. Participants were excluded if they had known immunity to varicella, hypersensitivity to blood or blood products, hypersensitivity to any component of VARIZIG, a history of selective immunoglobulin A deficiency, evidence of current varicella or herpes zoster infection at study entry, or evidence of severe thrombocytopenia. Participants with previous varicella immunity who had received an HCT were considered non-immune and could receive VARIZIG per the guidelines established by the Advisory Committee on Immunization Practices [9].

Study design and treatment
This expanded-access program (NCT00338442) was open-label and took place in a real-world setting at 285 clinical study sites across the United States between March 2006 and April 2013. Study visits occurred at baseline (to determine eligibility, administer VARIZIG, and monitor participants after exposure), between days 1 to 4, between days 7 to 20, and between days 28 to 42. VARIZIG (125 IU/10 kg [up to 625 IU]) was administered once intramuscularly. Ideally, administration occurred as soon as possible after exposure, but administration could occur within 10 days of exposure. This study was conducted in accordance with the Good Clinical Practice Guideline as defined by the International Conference on Harmonisation, the Declaration of
There were 40 immunocompromised adults included in the study (Table 1). Of these, 10 individuals (25%) had oncologic immunodeficiencies, 6 (15%) had primary immunodeficiencies, 5 (13%) had a history of SOT, 6 (15%) had a history of HCT, and 13 (32%) had other or unspecified immunocompromising conditions. Most exposures occurred in the household (53%) or the healthcare setting (40%); this pattern held for each subgroup, although the distribution varied to some degree, with SOT recipients more commonly exposed in the hospital (80%), whereas individuals with primary immunodeficiencies were more commonly exposed in the household (83%). There was a relatively equivalent distribution of type of exposure, with 48% exposed to varicella, 38% exposed to herpes zoster, and 15% with an “unknown” or “not specified” exposure in the case report form.

There were 263 immunocompromised children included in the study (Table 2). One hundred fifty-two (58%) had oncologic immunodeficiencies, with acute lymphocytic leukemia (n = 63) as the most common diagnosis, followed by pre-B acute lymphocytic leukemia (n = 13) and neuroblastoma (n = 15); all other causes occurred in seven or fewer patients each. There were 36 (14%) children with a history of SOT, 17 (6%) children with a history of HCT, 13 (5%) children with primary immunodeficiencies, and 45 (17%) children with other causes of immunodeficiency. Exposure to varicella or herpes zoster most commonly occurred in the healthcare setting (39%), the household (33%), and school/daycare (21%). Seventy-two percent of children were exposed to varicella, with 16% exposed to herpes zoster and 12% unknown/not specified exposure noted in the case report form.

### Results

#### Participants

There were 40 immunocompromised adults included in the study (Table 1). Of these, 10 individuals (25%) had oncologic immunodeficiencies, 6 (15%) had primary immunodeficiencies, 5 (13%) had a history of SOT, 6 (15%) had a history of HCT, and 13 (32%) had other or unspecified immunocompromising conditions. Most exposures occurred in the household (53%) or the healthcare setting (40%); this pattern held for each subgroup, although the distribution varied to some degree, with SOT recipients more commonly exposed in the hospital (80%), whereas individuals with primary immunodeficiencies were more commonly exposed in the household (83%). There was a relatively equivalent distribution of type of exposure, with 48% exposed to varicella, 38% exposed to herpes zoster, and 15% with an “unknown” or “not specified” exposure in the case report form.

There were 263 immunocompromised children included in the study (Table 2). One hundred fifty-two (58%) had oncologic immunodeficiencies, with acute lymphocytic leukemia (n = 63) as the most common diagnosis, followed by pre-B acute lymphocytic leukemia (n = 13) and neuroblastoma (n = 15); all other causes occurred in seven or fewer patients each. There were 36 (14%) children with a history of SOT, 17 (6%) children with a history of HCT, 13 (5%) children with primary immunodeficiencies, and 45 (17%) children with other causes of immunodeficiency. Exposure to varicella or herpes zoster most commonly occurred in the healthcare setting (39%), the household (33%), and school/daycare (21%). Seventy-two percent of children were exposed to varicella, with 16% exposed to herpes zoster and 12% unknown/not specified exposure noted in the case report form.

### Assessments

#### Assessment of varicella outcome

Patients were assessed for the development of varicella and any varicella-related complications, including but not limited to pulmonary disease and encephalitis. If present, varicella lesions were counted. Varicella was considered complicated if the participant developed more than 100 lesions, pulmonary disease, or encephalitis [16].

### Safety assessment

Safety was assessed throughout the study, including adverse events (AEs) and serious AEs as defined according to the Medical Dictionary for Regulatory Activities, version 16.0. All AEs were assessed for seriousness, severity, and causality by the investigator.

### Statistical analysis

Immunocompromised participants were grouped by age (children aged 18 years or younger and adults) and then stratified into five groups based on immunocompromising condition: “primary immunodeficiencies”, “oncologic immunodeficiencies”, “history of SOT”, “history of HCT”, and “other” immunodeficiencies. Data were analyzed using descriptive statistics.

### Results

#### Participants

There were 40 immunocompromised adults included in the study (Table 1). Of these, 10 individuals (25%) had oncologic immunodeficiencies, 6 (15%) had primary immunodeficiencies, 5 (13%) had a history of SOT, 6 (15%) had a history of HCT, and 13 (32%) had other or unspecified immunocompromising conditions. Most exposures occurred in the household (53%) or the healthcare setting (40%); this pattern held for each subgroup, although the distribution varied to some degree, with SOT recipients more commonly exposed in the hospital (80%), whereas individuals with primary immunodeficiencies were more commonly exposed in the household (83%). There was a relatively equivalent distribution of type of exposure, with 48% exposed to varicella, 38% exposed to herpes zoster, and 15% with an “unknown” or “not specified” exposure in the case report form.

There were 263 immunocompromised children included in the study (Table 2). One hundred fifty-two (58%) had oncologic immunodeficiencies, with acute lymphocytic leukemia (n = 63) as the most common diagnosis, followed by pre-B acute lymphocytic leukemia (n = 13) and neuroblastoma (n = 15); all other causes occurred in seven or fewer patients each. There were 36 (14%) children with a history of SOT, 17 (6%) children with a history of HCT, 13 (5%) children with primary immunodeficiencies, and 45 (17%) children with other causes of immunodeficiency. Exposure to varicella or herpes zoster most commonly occurred in the healthcare setting (39%), the household (33%), and school/daycare (21%). Seventy-two percent of children were exposed to varicella, with 16% exposed to herpes zoster and 12% unknown/not specified exposure noted in the case report form.

#### Varicella outcomes

Of the immunocompromised adults, 80% received VARIZIG within 96 h of varicella or herpes zoster exposure (Table 1). Across subgroups, this pattern was similar, although in adult SOT patients, 60% received VARIZIG in the first 96 h. Overall, immunocompromised adults had a 6% incidence of varicella (Fig. 1a). Within subgroups, adults with oncologic immunodeficiencies had a 10% incidence of varicella and adults with other immunodeficiencies had a 9% incidence of varicella. No patients with primary immunodeficiencies, history of SOT, or history of developed varicella. Varicella outcome data were not available for four adults (two were in the primary immunodeficiency subgroup and two were in the other immunodeficiencies subgroup); these patients were excluded from incidence calculations. Timing of administration did not greatly impact the varicella incidence in adults (Fig. 1b). There were no varicella-related complications (> 100 lesions, pneumonia, or encephalitis) or hospitalizations in immunocompromised adults. Overall, four adults (10%) were treated prophylactically with antiviral therapy, with one patient in the oncologic immunodeficiency subgroup and three patients in the HCT subgroup; none of these patients developed varicella. Antiviral dosing regimens varied, with two patients dosed within the first 2 days of varicella or herpes zoster exposure for a duration of 3 weeks, and two patients were given antiviral therapy 7 days after varicella or herpes zoster exposure for unknown duration (i.e. treatment was still ongoing at study completion).

Ninety percent of immunocompromised children were administered VARIZIG within 96 h of varicella or herpes zoster exposure, this pattern was similar in all subgroups (Table 2). Overall, immunocompromised children had a 7% incidence of varicella (Fig. 1a). This incidence was similar in the subgroup of children with oncologic immunodeficiencies (5%), and children with a history of HCT (6%). Varicella incidence was greater in children with primary immunodeficiencies (15%) and children...
with a history of SOT (12%). Children with “other”
immunocompromising conditions had a 3% incidence of
varicella. Varicella outcome data were not available for
18 children (oncologic immunodeficiency, n = 4; SOT,
n = 3; other, n = 11); these children were excluded from
incidence calculations. When assessed by timing of
VARIZIG administration, all cases of varicella occurred
in patients who were administered VARIZIG within 96 h
of varicella or herpes zoster exposure. Varicella infec-
tions were mild, with only two patients developing more
than 100 lesions, and no cases of varicella-related pul-
monary disease or encephalitis occurred. Most children
with oncologic immunodeficiencies who developed vari-
cella (6 of 8 children) and one child with history of SOT
were hospitalized for varicella treatment; there were no
varicella-related hospitalizations in children with primary
immunodeficiencies, history of HCT, or children with
other immunodeficiencies. Overall, 49 children
(19%) were treated prophylactically with antiviral ther-
apy, of whom 2 were in the primary immunodeficiency
subgroup, 32 in the oncologic immunodeficiency group,
6 in the SOT group, 4 in the HCT group, and 5 in the
“other” subgroup; none of these patients developed vari-
cella. Antiviral therapy (acyclovir or valacyclovir) was
most often dosed (orally or intravenously) in two differ-
ent regimens: patients were either given antiviral therapy
immediately (within 2 days) after exposure for a duration
of 2 days to > 1 month, or patients were given antiviral

Table 1 Baseline demographics and characteristics in immunocompromised adults

| Characteristic                        | Type of immune-compromising condition, n (%) |
|--------------------------------------|---------------------------------------------|
|                                      | All (n = 40) | Primary immunodeficiencya (n = 6) | Oncologic immunodeficiencya (n = 10) | Solid organ transplantc (n = 5) | Hematopoietic cell transplantc (n = 6) | Otherc (n = 13) |
| Age, years                           |            |                                |                                   |                              |                                  |                  |
| Mean (SD)                            | 44.3 (17.4) | 45.2 (14.6)                    | 43.7 (19.3)                       | 50.8 (15.2)                     | 53.3 (18.2)                       | 37.5 (17.1)       |
| Median (range)                       | 41 (18–75)  | 48 (29–61)                     | 46 (18–68)                       | 49 (35–71)                      | 61 (24–70)                       | 37 (18–75)        |
| Sex                                  |            |                                |                                   |                              |                                  |                  |
| Female                               | 19 (48)    | 3 (50)                        | 4 (40)                           | 2 (40)                         | 2 (33)                           | 8 (62)            |
| Male                                 | 21 (53)    | 3 (50)                        | 6 (60)                           | 3 (60)                         | 4 (67)                           | 5 (38)            |
| Race                                 |            |                                |                                   |                              |                                  |                  |
| White                                | 25 (63)    | 4 (67)                        | 7 (70)                           | 5 (100)                        | 2 (33)                           | 7 (54)            |
| Hispanic/Latino                      | 4 (10)     | 0                             | 2 (20)                           | 0                              | 0                               | 2 (15)            |
| Black/African American               | 5 (13)     | 1 (17)                        | 1 (10)                           | 0                              | 2 (33)                           | 1 (8)             |
| Asian                                | 2 (5)      | 0                             | 0                                | 0                              | 1 (17)                           | 1 (8)             |
| Unknown/Not reported                 | 4 (10)     | 1 (17)                        | 0                                | 0                              | 1 (17)                           | 2 (15)            |
| Location of VZV exposure             |            |                                |                                   |                              |                                  |                  |
| Household                            | 21 (53)    | 5 (83)                        | 5 (50)                           | 1 (20)                         | 3 (50)                           | 5 (38)            |
| Healthcare setting                   | 16 (40)    | 0                             | 4 (40)                           | 4 (80)                         | 3 (50)                           | 7 (54)            |
| School                               | 1 (2)      | 0                             | 0                                | 0                              | 0                               | 1 (8)             |
| Unknown                              | 2 (5)      | 1 (17)                        | 1 (10)                           | 0                              | 0                               | 0                 |
| Type of VZV exposure                 |            |                                |                                   |                              |                                  |                  |
| Varicella                            | 19 (48)    | 3 (50)                        | 7 (70)                           | 1 (20)                         | 1 (17)                           | 7 (54)            |
| Herpes zoster                        | 15 (38)    | 2 (33)                        | 1 (10)                           | 4 (80)                         | 4 (67)                           | 4 (31)            |
| Unknown/not specifiedf               | 6 (15)     | 1 (17)                        | 2 (20)                           | 0                              | 1 (17)                           | 2 (15)            |
| Timing of VARIZIG administration     |            |                                |                                   |                              |                                  |                  |
| < 96 h after exposure                | 32 (80)    | 5 (83)                        | 9 (90)                           | 3 (60)                         | 5 (83)                           | 10 (77)           |
| 5–10 days after exposure             | 8 (20)     | 1 (17)                        | 1 (10)                           | 2 (40)                         | 1 (16)                           | 3 (23)            |

Some characteristics may not total 100% because of rounding
aIncludes participants with primary immunodeficiencies (HIV infection/AIDS [n = 2], hypogammaglobulinemia [n = 2], immunodeficiency common variable [n = 2])
bIncludes participants with oncologic conditions
cIncludes participants who have undergone SOT and are taking anti-rejection medication
dIncludes participants who have undergone HCT
fParticipants had known VZV exposure but type of VZV (either varicella zoster or herpes zoster) was not specified or known

with a history of SOT (12%). Children with “other”
immunocompromising conditions had a 3% incidence of
varicella. Varicella outcome data were not available for
18 children (oncologic immunodeficiency, n = 4; SOT,
n = 3; other, n = 11); these children were excluded from
incidence calculations. When assessed by timing of
VARIZIG administration, all cases of varicella occurred
in patients who were administered VARIZIG within 96 h
of varicella or herpes zoster exposure. Varicella infec-
tions were mild, with only two patients developing more
than 100 lesions, and no cases of varicella-related pul-
monary disease or encephalitis occurred. Most children
with oncologic immunodeficiencies who developed vari-
cella (6 of 8 children) and one child with history of SOT
were hospitalized for varicella treatment; there were no
varicella-related hospitalizations in children with primary
immunodeficiencies, history of HCT, or children with
other immunodeficiencies. Overall, 49 children
(19%) were treated prophylactically with antiviral ther-
apy, of whom 2 were in the primary immunodeficiency
subgroup, 32 in the oncologic immunodeficiency group,
6 in the SOT group, 4 in the HCT group, and 5 in the
“other” subgroup; none of these patients developed vari-
cella. Antiviral therapy (acyclovir or valacyclovir) was
most often dosed (orally or intravenously) in two differ-
ent regimens: patients were either given antiviral therapy
immediately (within 2 days) after exposure for a duration
of 2 days to > 1 month, or patients were given antiviral
therapy approximately 6 to 10 days after exposure, for a duration of 2 to 3 weeks. A small group of patients were already on antiviral therapy for underlying medical conditions. If patients who received prophylactic antiviral therapy are excluded from the analysis, varicella incidence is not markedly changed (overall pediatric population: 7.5% [16 of 214 participants], oncologic: 6.7% [8 of 120 participants], history of HCT: 7.7% [1 of 13 participants], SOT: 13.3% [4

| Characteristic                      | Type of immune-compromising condition, n (%) |
|-------------------------------------|---------------------------------------------|
|                                     | All (n = 263) | Primary immunodeficiencya (n = 13) | Oncologic immunodeficiencyb (n = 152) | Solid organ transplantc (n = 36) | Hematopoietic cell transplanthead (n = 17) | Other* (n = 45) |
| Age, years                          |              |                                |                                  |                                |                                         |                |
| Mean (SD)                           | 6.4 (4.6)    | 7.8 (5.3)                       | 6.0 (4.4)                        | 7.2 (4.4)                       | 5.9 (3.7)                                 | 6.8 (5.6)      |
| Median (range)                      | 6 (0–17)     | 6 (0.83–17)                     | 5 (0.25–17)                      | 6 (0.5–16)                      | 6 (1–14)                                  | 7 (0–17)       |
| Sex                                 |              |                                |                                  |                                |                                         |                |
| Female                              | 125 (48)     | 4 (21)                          | 78 (51)                          | 15 (42)                         | 6 (35)                                    | 22 (49)        |
| Male                                | 138 (52)     | 9 (69)                          | 74 (49)                          | 21 (58)                         | 11 (65)                                   | 23 (51)        |
| Race                                |              |                                |                                  |                                |                                         |                |
| White                               | 163 (62)     | 8 (62)                          | 91 (60)                          | 26 (72)                         | 10 (59)                                   | 28 (62)        |
| Hispanic/Latino                     | 47 (18)      | 0                               | 34 (22)                          | 5 (14)                          | 3 (18)                                    | 5 (11)         |
| Black/African American              | 32 (12)      | 4 (31)                          | 18 (12)                          | 2 (6)                           | 2 (12)                                    | 6 (13)         |
| Asian                               | 5 (2)        | 0                               | 3 (2)                            | 0                               | 0                                         | 2 (4)          |
| American Indian/Alaskan native      | 2 (1)        | 0                               | 1 (1)                            | 0                               | 1 (6)                                     | 0              |
| Unknown/Not reported                | 14 (5)       | 1 (8)                           | 5 (3)                            | 3 (8)                           | 1 (6)                                     | 4 (9)          |
| Location of VZV exposure            |              |                                |                                  |                                |                                         |                |
| Household                           | 87 (33)      | 8 (62)                          | 41 (27)                          | 17 (47)                         | 8 (47)                                    | 13 (29)        |
| Healthcare setting                  | 102 (39)     | 2 (15)                          | 75 (49)                          | 8 (22)                          | 5 (29)                                    | 13 (29)        |
| School/daycare/playgroup            | 55 (21)      | 1 (8)                           | 25 (16)                          | 11 (31)                         | 2 (12)                                    | 16 (36)        |
| Otherf                             | 12 (5)       | 2 (15)                          | 8 (5)                            | 0                               | 1 (6)                                     | 1 (2)          |
| Unknown                            | 6 (2)        | 0                               | 3 (2)                            | 0                               | 1 (6)                                     | 2 (4)          |
| Type of VZV exposure                |              |                                |                                  |                                |                                         |                |
| Varicella                           | 190 (72)     | 9 (69)                          | 109 (72)                         | 30 (83)                         | 10 (59)                                   | 32 (71)        |
| Herpes zoster                       | 41 (16)      | 1 (8)                           | 24 (16)                          | 5 (14)                          | 4 (24)                                    | 7 (16)         |
| Unknown/not specifiedg              | 32 (12)      | 3 (23)                          | 19 (13)                          | 1 (3)                           | 3 (18)                                    | 6 (13)         |
| Timing of VARIZIG administration    |              |                                |                                  |                                |                                         |                |
| < 96 h after exposure               | 237 (90)     | 11 (85)                         | 136 (89)                         | 34 (94)                         | 16 (94)                                   | 40 (89)        |
| 5–10 days after exposure            | 25 (10)      | 2 (15)                          | 15 (10)                          | 2 (6)                           | 1 (6)                                     | 5 (11)         |
| Unknown                            | 1 (0.4)      | 0                               | 1 (1)                            | 0                               | 0                                         | 0              |

Some characteristics may not total 100% because of rounding.

*aIncludes participants with primary immunodeficiencies (cell-mediated immune deficiency [n = 1], combined immunodeficiency [n = 2], DiGeorge syndrome [n = 2], HIV infection/AIDS [n = 2], immunodeficiency common variable [n = 3], neutropenia [n = 1], tumor necrosis factor receptor–associated periodic syndrome [n = 1], and Wiskott-Aldrich syndrome [n = 1]).

*bIncludes participants who have undergone SOT and are taking anti-rejection medication.

*cIncludes participants who have undergone HCT.

*Includes participants with other immunocompromising conditions (adrenoleukodystrophy [n = 1], aplastic anemia [n = 3], anemia [n = 2], aplasia pure red cell [n = 1], arthritis [n = 1], asthma [n = 2], cardiac operation [n = 1], chronic granulomatous disease [n = 1], Cushingoid [n = 1], Evan’s syndrome [n = 1], focal segmental glomerulosclerosis [n = 1], Goodpasture’s syndrome [n = 1], Henoch-Schönlein purpura nephritis [n = 1], hypoplastic left heart syndrome [n = 1], juvenile-onset arthritis [n = 4], McKusick-Kaufman syndrome [n = 1], lupus nephritis [n = 1], nephrotic syndrome [n = 4], ornithine transcarbamylase deficiency [n = 1], polyarteritis nodosa [n = 1], premature baby [n = 7], sarcoidosis [n = 1], thrombocytopenia [n = 1], ulcerative colitis [n = 1], uveitis [n = 1], velocardiofacial syndrome [n = 1], and unknown/unspecified [n = 3]).

*fOther locations of exposure included camp or sporting events.

*gParticipants had known VZV exposure but type of VZV (either varicella zoster or herpes zoster) was not specified or known.
of 30 participants], primary immunodeficiencies: 18.2% [2 of 11 participants], and other immunodeficiencies: 2.5% [1 of 40 participants].

Safety

Overall, 15 immunocompromised adults (38%) experienced 51 AEs, of which only one AE of nausea was considered related to VARIZIG (Table 3). Four adults (10%) experienced 10 serious AEs, none of which were considered related to VARIZIG. There was one death (respiratory failure in a patient with AIDS) in the immunocompromised adult group; this death was considered unrelated to varicella or VARIZIG.

In the group of immunocompromised children, 90 (34%) experienced 402 AEs, of which 53 (13%) were considered related to VARIZIG (Table 4). The most frequently occurring (in more than one participant) AEs that were considered related to VARIZIG were injection site pain (n = 5, 2%), headache (n = 2, 0.8%), and diarrhea (n = 2, 0.8%). There were 42 children (16%) who experienced 93 serious AEs, of which one (serum sickness) was considered related to VARIZIG. There were five deaths: three (caused by acute myeloid leukemia, intracranial hemorrhage, and neuroblastoma) occurred in the oncologic immunodeficiency group, one (caused by acute lymphoblastic leukemia complicated by pneumonia infection) occurred in the group with a history of HCT, and one (caused by congestive cardiac failure) occurred in the “other” immunocompromised group. None of these deaths were considered by the investigators to be related to varicella or VARIZIG.
Discussion

Immunocompromised individuals are more susceptible to severe varicella-related complications, accounting for more than 90% of varicella-related hospital admissions [17]. With increasing numbers of immunocompromised individuals [7, 8] who cannot be vaccinated [9] or lose vaccine-induced immunity due to immunosuppressive therapies [18], there is an ever-present need for protection after varicella or herpes zoster exposure, with passive immunization providing a safe and efficacious strategy in other populations. However, there are limited clinical data published on the use of VARIZIG and the impact on varicella-related outcomes. This analysis reports data from an expanded-access program in subgroups of adult and pediatric immunocompromised patients.

The overall incidence of varicella was 6% in adult immunocompromised patients, and 7% in pediatric immunocompromised patients. Similar incidences occurred in subgroups of patients stratified by type of immunocompromising condition. These incidences are similar to those reported historically in immunocompromised patients. In a 24-year retrospective study of 5777 pediatric patients with cancer, the incidence of varicella was 5% (just 45 of these patients received immunoglobulin prophylaxis) [10]. In 93 adults with multiple myeloma who were receiving lenalidomide, 10 (10.7%) developed varicella infection, and in 132 patients with multiple myeloma who had undergone allogenic HCT, 10 (7.6%) developed varicella infection [1].

Although similar incidences of varicella were reported compared with historical data, one of the benefits of passive immunization lies in its ability to attenuate disease severity in immunocompromised individuals. In immunocompromised participants in this expanded-access program, most cases of varicella were mild; just two children developed varicella with more than 100 lesions, there were no cases of varicella-related complications, and there were no varicella-related deaths. In a pre-vaccination era study that monitored varicella cases (N = 77) in immunocompromised children over 11 years, the rate of visceral dissemination was 32%, with mortality occurring in 7% of patients [3]. In the 24-year retrospective study cited above, varicella-related pneumonia occurred in 28% of patients with varicella, with an overall mortality rate of 7% [10]. Another study in immunocompromised children (both oncologic and other causes) reported a 14% varicella-related mortality rate [19]. Retrospective chart reviews of immunocompromised children reported rates of visceral dissemination as high as 21% [20] and 48% [21], with a 14% [20] mortality rate. Data from the US Mortality Multiple Cause of Death public use records (from the National Center for Health Statistics) indicate a total of 155 suspected varicella deaths from 1996 to 2013 from 34 states; of the 77 deaths in which immune status was known, 24 deaths (29%) occurred in immunocompromised persons [22]. Half of the reported deaths occurred in patients with immunocompromising conditions and the other half were in patients being treated with an immunocompromising medication [22]. From 1999 to

| Table 3 | Safety in immunocompromised adults |
|---------|-----------------------------------|
| Preferred term | Type of immune-compromising condition, n (%) |
| All (n = 40) | Primary immunodeficiencya (n = 6) | Oncologic immunodeficiencyb (n = 10) | Solid organ transplantc (n = 5) | Hematopoietic cell transplantd (n = 6) | Othere (n = 13) |
| AEs | |
| Participants, n (%) | 15 (38) | 3 (50) | 2 (20) | 1 (20) | 3 (50) | 6 (46) |
| Total AEs, n | 1 | 0 | 1 | 0 | 0 | 0 |
| Total related AEs, n | 1 | 0 | 1 | 0 | 0 | 0 |
| All related AEs, n (%) | |
| Nausea | 1 (3) | 0 | 1 (10) | 0 | 0 | 0 |
| Serious AEs | |
| Participants, n (%) | 4 (10) | 1 (17) | 1 (10) | 0 | 0 | 2 (15) |
| Total serious AEs, n | 10 | 1 | 2 | 0 | 0 | 7 |
| Total related serious AEs, n | 0 | 0 | 0 | 0 | 0 | 0 |
| Deaths, n (%)f | 1 (3) | 1 (17) | 0 | 0 | 0 | 0 |

aIncludes participants with primary immunodeficiencies (e.g. HIV infection/AIDS, hypogammaglobulinemia, immunodeficiency common variable)
bIncludes participants with oncologic immunodeficiencies

Includes participants who have undergone SOT and are taking anti-rejection medication
dIncludes participants who have undergone HCT

eIncludes participants with other immunocompromising conditions (e.g. multiple sclerosis, lupus nephritis, adrenoleukodystrophy, chronic renal failure, asthma, juvenile-onset arthritis)
fDeath was due to respiratory failure in a woman with AIDS; death was considered unrelated to varicella or VARIZIG
2007, deaths occurred in a greater number of involved immunocompromised patients (29%) than deaths reported for immunocompetent individuals (11–18%) [22]. Although vaccination has been shown to reduce the incidence of complications and varicella-related hospitalizations overall, a German varicella surveillance project noted significantly more varicella-related complications in immunocompromised patients, including hematologic complications and systemic bacterial infections [23]. Even with vaccination becoming common practice in many countries, a systematic review of breakthrough varicella noted severe breakthrough disease in healthy and immunocompromised children [24]. Because of bone marrow transplant, previously vaccinated oncology patients may be rendered non-immune [18], therefore increasing their risk for severe varicella infection.

In immunocompromised adults, there was a similar incidence of varicella when comparing the timing of VARIZIG administration post-exposure (3% incidence with administration within and after 96 h post-exposure), much like the pattern reported in the overall study population [15]. However, we report here that in immunocompromised children, all cases of varicella occurred in patients who were administered VARIZIG within 96 h of exposure to varicella or herpes zoster. This may represent a more significant or known varicella or herpes zoster exposure that prompted more aggressive access to care; however, it should be noted that 90% of immunocompromised children were administered VARIZIG within 96 h of exposure.

The results from this analysis demonstrate that VARIZIG is well tolerated and safe in immunocompromised adults and children, confirming previously published, positive safety findings in high-risk patient populations [15]. The proportion of immunocompromised adult and pediatric patients who experienced any AE was similar (38 and 34%, respectively), as well as the proportion of patients with AEs and serious AEs that were considered related to VARIZIG. Most commonly occurring AEs deemed related to VARIZIG are expected adverse drug
reactions for immune globulin products (e.g. injection site pain) and/or could be exacerbated by medications used to treat the patient’s underlying condition (e.g. headache, nausea, and vomiting).

This study was limited by the expanded-access, open-label, uncontrolled study design. Some of the limitations of the study did not always identify the type of exposure (e.g. varicella vs herpes zoster). In addition, varicella outcome data are missing for some participants, either because they withdrew early or were lost to follow-up before varicella infection could have developed. In this real-world setting, each physician determined whether the exposure qualified as needing prophylaxis and it is unclear if all cases would have resulted in the development of varicella; as such, these data need to be interpreted carefully. In addition, several participants received VARIZIG and antiviral therapy targeted against varicella or other viral infections; thus, the role of each of these interventions in varicella prevention in these individuals cannot be determined.

In conclusion, these data indicate that passive immunization with VARIZIG may prevent and/or reduce disease severity in immunocompromised children and adults, supporting its use for disease prevention in exposed high-risk individuals. Clinicians should be aware that patients who previously received two doses of varicella vaccine may no longer be immune after immunosuppressive therapies or after undergoing SOT or HCT [6]; as a result, previous immunity to varicella through vaccination should not always be a factor when considering treatment with VARIZIG if patients have undergone immunosuppressive treatment.

Abbreviations
AE: Adverse event; HCT: Hematopoietic cell transplant; SOT: Solid organ transplant; VARIZIG: Varicella zoster immune globulin (human); VZV: Varicella zoster virus

Acknowledgements
The authors thank Kelly M. Cameron, PhD, CMPP™, of JB Ashtin, who developed the first draft based on an author-approved outline and assisted in implementing author revisions.

Authors’ contributions
HG and RFC were equally involved in developing the concept of the manuscript, interpreting the data, and reviewing and approving the final manuscript for publication.

Funding
This work was supported by Cangene Corporation, Winnipeg, Canada (manufacturer and initial owner of VARIZIG [varicella zoster immune globulin (human)]). Cangene was involved in study design and conduct. Saol Therapeutics funded the subsequent independent data analysis, interpretation, medical writing support, and participated in the decision to submit the article for publication. Saol was involved in the review of the article for medical accuracy, but the final content was left to the discretion of the authors.

Availability of data and materials
The data underlying this study belong to Saol Therapeutics. Interested researchers can send data access requests to info@saolnx.com.

Ethics approval and consent to participate
This study was conducted in accordance with the Good Clinical Practice Guideline as defined by the International Conference on Harmonisation, the Declaration of Helsinki, and all applicable federal and local regulations and institutional review board guidelines. The protocol and amendments, the informed consent form, and study-related materials were reviewed and approved by a central independent ethics committee (Western Institutional Review Board, Puyallup, WA, USA) before study initiation and throughout the conduct of the study. All patients (or their guardians) provided written informed consent.

Consent for publication
Not applicable.

Competing interests
HG has received funding/grant support from National Vaccine Program Office, National Institutes of Health, and honorarium for consultancy from US Department of Health and Human Services. RFC has received funding/grant support paid to his institution from Merck, Chimerix, Viracor, Oxford Immunotec, Xenex, Gilead, Ansum Pharmaceuticalls, Shire/Takeda, and Alacuris, and honorarium for consultancy from Xenex, Merck, Chimerix, Shire/Takeda, Ansum Pharmaceuticalls, Pulmocite, Clingen, Oxford Immunotec, ReViral, Kyorin, Genentech, and Janssen.

Author details
1Departments of Pediatrics and Division of Infectious Diseases, Stanford University School of Medicine, 300 Pasteur Drive, Unit G312, Stanford, CA 94305, USA. 2Department of Infectious Diseases, Infection Control, and Employee Health, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd Unit 402, Houston, TX 77030, USA.

Received: 18 June 2020 Accepted: 24 November 2020
Published online: 11 January 2021

References
1. König C, Kleber M, Reinhardt H, Knop S, Wasch R, Engelhardt M. Incidence, risk factors, and implemented prophylaxis of varicella zoster virus infection, including complicated varicella zoster virus and herpes simplex virus infections, in lenalidomide-treated multiple myeloma patients. Ann Hematol. 2014;93(3):479–84.
2. Brown AEC, Asturias EJ, Melgar M, Antillon-Klussmann FA, Mettler P, Levin MJ. Incidence and consequences of varicella in children treated for cancer in Guatemala. World J Pediatr. 2016;12(3):320–6.
3. Feldman S, Hughes WT, Daniel CB. Varicella in children with cancer: seventy-seven cases. Pediatrics. 1975;56(3):388–97.
4. Strauss SE, Ostrove JM, Inchauspe G, Selzer JM, Freedfeld A, Croen KD, Sawyer MH, NIH conference. Varicella-zoster virus infections. Biology, natural history, treatment, and prevention. Ann Intern Med. 1988;108(2):221–37.
5. Leuvenink R, Aeschlimann F, Baur W, Berthet G, Cannizzaro E, Hofer M, Kaiser D, Schroeder S, Heiningger U, Woerner A. Clinical course and therapeutic approach to varicella zoster virus infection in children with rheumatic autoimmune diseases under immunosuppression. Pediatr Rheumatol Online J. 2016;14(1):34.
6. Sewnainline M, Rajan S, Redner A, Rubin LG. Varicella in a previously immune patient with leukemia. J Pediatric Infect Dis Soc. 2017;6(2):e4–6.
7. Harpaz R, Dahl RM, Dooling KL. Prevalence of immunosuppression among US adults, 2013. JAMA. 2016;316(23):2547–8.
8. Shetty AK, Winter MA. Immunization of children receiving immunosuppressive therapy for cancer or hematopoietic stem cell transplantation. Ochsner J. 2012;12(3):228–43.
9. Marin M, Guris D, Chaves SS, Schmid S, Seward JF. Advisory Committee on Immunization Practices CDC. Prevention. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2007;56(RR-4):1–40.
10. Feldman S, Lott L. Varicella in children with cancer: impact of antiviral therapy and prophylaxis. Pediatrics. 1987;80(4):645–72.
11. Zaia JA, Levin MJ, Preblud SR, Leszczynski J, Wright GG, Ellis RJ, Curtis AC, Valerio MA, LeGore J. Evaluation of varicella-zoster immune globulin protection of immunosuppressed children after household exposure to varicella. J Infect Dis. 1983;147(4):737–43.
12. Centers for Disease Control and Prevention. Updated recommendations for use of Varizig—United States, 2013. MMWR Morb Mortal Wkly Rep. 2013;62(28):574–6.

13. Suga S, Yoshikawa T, Ozaki T, Asano Y. Effect of oral acyclovir against primary and secondary viraemia in incubation period of varicella. Arch Dis Child. 1993;69(5):639–42 discussion 42–3.

14. Varizig(R) (varicella zoster immune globulin [human]). Prescribing information. Saol Therapeutics Inc., Roswell, GA. [https://varizig.com/VARIZIG_PI.pdf].

15. Levin MJ, Duchon JM, Swamy GK, Gershon AA. Varicella zoster immune globulin (Varizig) administration up to 10 days after varicella exposure in pregnant women, immunocompromised participants, and infants: varicella outcomes and safety results from a large, open-label, expanded-access program. PLoS One. 2019;14(7):e0217749.

16. Karadag Oncel E, Kara A, Celik M, Karahan S, Cengiz AB, Ceyhan M. Determination and clinical correlation of markers of inflammation in unvaccinated patients with varicella-zoster infection. Eur Rev Med Pharmacol Sci. 2013;17(S1):2032–9.

17. Hobbelen PH, Stowe J, Amirthalingam G, Miller L, van Hoek AJ. The burden of hospitalisation for varicella and herpes zoster in England from 2004 to 2013. J Inf Secur. 2016;73(3):241–53.

18. Toret E, Yel SE, Suman M, Duzenli Kar Y, Ozdemir ZC, Dinleyici M, Bor O. Immunization status and re-immunization of childhood acute lymphoblastic leukemia survivors. Hum Vaccin Immunother. 2020;1–4.

19. Finkel KC. Mortality from varicella in children receiving adrenocorticosteroids and adrenocorticotropin. Pediatrics. 1961;28:436–41.

20. Geiser CF, Bishop Y, Myers M, Jaffe N, Yankee R. Prophylaxis of varicella in children with neoplastic disease: comparative results with zoster immune plasma and gamma globulin. Cancer. 1975;35(4):1027–30.

21. Morgan ER, Smallay LA. Varicella in immunocompromised children. Incidence of abdominal pain and organ involvement. Am J Dis Child. 1983;137(9):883–5.

22. Leung J, Bialek SR, Marin M. Trends in varicella mortality in the United States: data from vital statistics and the national surveillance system. Hum Vaccin Immunother. 2015;11(3):662–8.

23. Hagemann C, Klam A, Grote V, Liese JG, Streng A. Specific varicella-related complications and their decrease in hospitalized children after the introduction of general varicella vaccination: results from a multicenter pediatric hospital surveillance study in Bavaria (Germany). Infect Dis Ther. 2019;8(4):597–611.

24. Leung J, Broder KR, Marin M. Severe varicella in persons vaccinated with varicella vaccine (breakthrough varicella): a systematic literature review. Expert Rev Vaccines. 2017;16(4):391–400.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.